The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design

2017/12/01 by EMILY M. CARDEW, Emily Cardew, CHRISTOPHE L. M. J. VERLINDE +3 · 1 citation
Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · Chemistry · #Toxoplasma gondii Research Studies #Venomous Animal Envenomation and Studies #Synthesis and Characterization of Heterocyclic Compounds

paper · pdf · doi:10.1017/s0031182017001901

Abstract

The apicomplexan protozoan parasites include the causative agents of animal and human diseases ranging from malaria (Plasmodium spp.) to toxoplasmosis (Toxoplasma gondii). The complex life cycle of T. gondii is regulated by a unique family of calcium-dependent protein kinases (CDPKs) that have become the target of intensive efforts to develop new therapeutics. In this review, we will summarize structure-based strategies, recent successes and future directions in the pursuit of specific and selective inhibitors of T. gondii CDPK1.

Citations

• Toxoplasmosis: A history of clinical observations

Cited by

• An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii

Related

• Toxoplasma gondii as a drug for anti-tumor immunotherapy: mechanisms, challenges, and perspectives
• Molecular Modeling of the Toxoplasma Gondii Adenosine Kinase Inhibitors
• Furanocarboxamide Derivative Against Congenital Toxoplasmosis: Synthesis, Bioactivity, ADME Profile and in silico Insights
• Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites
• Computational Motility Tracking of Calcium Dynamics in Toxoplasma gondii